RightFit
RecruitingPhase 2

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 80 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests tulisokibart (MK-7240) in adults with active psoriatic arthritis, a disease that causes joint pain and swelling. Researchers will compare different doses with a placebo, which looks like the medicine but has no study medicine in it. They will see if it eases symptoms and check its safety and side effects.

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have psoriatic arthritis that meets the study’s diagnosis rules, with symptoms starting at least 6 months before screening.
  • Have plaque psoriasis now or a documented history of it. This skin condition causes thick, scaly patches.
  • Have never used biologic medicines for arthritis, or these medicines did not work well enough or caused side effects you could not tolerate.

Who can't join

  • Had any arthritis start before age 17.
  • Have another disease that causes joint inflammation, or another condition that could make psoriatic arthritis hard to assess.
  • Have a skin condition other than psoriasis that could make psoriasis hard to assess.
  • Have had cancer and have been cancer-free for less than 5 years before study group assignment. Exceptions include fully treated nonmelanoma skin cancer and early cervical cancer that had not spread and was fully removed by surgery.
  • Have any active infection.
  • Have a known allergy to tulisokibart or its ingredients, or cannot tolerate them.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening. * Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis. * Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response/intolerant. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than PsA (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myositis, etc), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of PsA. * Has a skin condition diagnosis, other than psoriasis that may, in the judgment of the investigator, interfere with the assessment of psoriasis. * Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before Randomization. * Has any active infection. * Has known allergies, hypersensitivity, or intolerance to tulisokibart of its excipients.

Study sites (18)

AZ

CA

FL

ID

MD

MO

NC

NE

NY

PA

SC

TX